Implication of tumor microenvironment in chemoresistance: Tumor-associated stromal cells protect tumor cells from cell death

International Journal of Molecular Sciences

Volumn 13, Issue 8, 2012, Pages 9545-9571

  Castells, Magali ^a,b   Thibault, Benoît ^a,b   Delord, Jean Pierre ^a,b   Couderc, Bettina ^a,b  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Apoptosis; Cancer; Chemoresistance; Microenvironment

Indexed keywords

ANGIOGENESIS INHIBITOR; CISPLATIN; DOXORUBICIN; MICRORNA; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2 INHIBITOR;

ADIPOCYTE; ANGIOGENESIS; APOPTOSIS; BONE MARROW DERIVED STEM CELL; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CARCINOMA ASSOCIATED FIBROBLAST; CD8+ T LYMPHOCYTE; CELL ADHESION; CELL DEATH; CELL INTERACTION; CELL PROTECTION; CELL SURVIVAL; CYTOKINE RELEASE; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GAMMA DELTA T LYMPHOCYTE; HELPER CELL; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; MACROPHAGE; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MESENCHYMAL STEM CELL; MYOFIBROBLAST; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; STEM CELL; STROMA CELL; TUMOR ASSOCIATED STROMAL CELL; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL CULTURE;

ANIMALS; CELL DEATH; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; STROMAL CELLS; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT;

EID: 84865036227     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13089545     Document Type: Review

References (132)

1. Meads, M.B.; Gatenby, R.A.; Dalton, W.S. Environment-mediated drug resistance: A major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9, 665-674.
2. Basak, G.W.; Srivastava, A.S.; Malhotra, R.; Carrier, E. Multiple myeloma bone marrow niche. Curr. Pharm. Biotechnol. 2009, 3, 345-346.
3. Roodhart, J.M.; Daenen, L.G.; Stigter, E.C.; Prins, H.J.; Gerrits, J.; Houthuijzen, J.M.; Gerritsen, M.G.; Schipper, H.S.; Backer, M.J.; van Amersfoort, M., et al. Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids. Cancer Cell 2011, 3, 370-383.
4. Castells, M.; Thibault, B.; Mery, E.; Golzio, M.; Pasquet, M.; Hennebelle, I.; Bourin, P.; Mirshahi, M.; Delord, J.P.; Querleu, D., et al. Ovarian ascites-derived Hospicells promote angiogenesis via activation of macrophages. Cancer Lett. 2012, in press.
5. Lis, R.; Touboul, C.; Mirshahi, P.; Ali, F.; Mathew, S.; Nolan, D.J.; Maleki, M.; Abdalla, S.A.; Raynaud, C.M.; Querleu, D., et al. Tumor associated mesenchymal stem cells protects ovarian cancer cells from hyperthermia through CXCL12. Int. J. Cancer 2011, 3, 715-725.
6. Scherzed, A.; Hackenberg, S.; Froelich, K.; Kessler, M.; Koehler, C.; Hagen, R.; Radeloff, A.; Friehs, G.; Kleinsasser, N. BMSC enhance the survival of paclitaxel treated squamous cell carcinoma cells in vitro. Cancer Biol. Ther. 2011, 3, 349-357.
7. Rafii, A.; Mirshahi, P.; Poupot, M.; Faussat, A.M.; Simon, A.; Ducros, E.; Mery, E.; Couderc, B.; Lis, R.; Capdet, J., et al. Oncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumours. PLoS.One 2008, 12, e3894.
8. Rohwer, N.; Cramer, T. Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist.Updat. 2011, 3, 191-201.
9. Tredan, O.; Galmarini, C.M.; Patel, K.; Tannock, I.F. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007, 19, 1441-1454.
10. Teng, I.W.; Hou, P.C.; Lee, K.D.; Chu, P.Y.; Yeh, K.T.; Jin, V.X.; Tseng, M.J.; Tsai, S.J.; Chang, Y.S.; Wu, C.S., et al. Targeted methylation of two tumor suppressor genes is sufficient to transform mesenchymal stem cells into cancer stem/initiating cells. Cancer Res. 2011, 13, 4653-4663.
11. Correia, A.L.; Bissell, M.J. The tumor microenvironment is a dominant force in multidrug resistance. Drug Resist.Updat. 2012, 15, 39-49.
12. Sutherland, R.M.; Eddy, H.A.; Bareham, B.; Reich, K.; Vanantwerp, D. Resistance to adriamycin in multicellular spheroids. Int. J. Radiat.Oncol. Biol. Phys. 1979, 8, 1225-1230.
13. Stoeck, A.; Gast, D.; Sanderson, M.P.; Issa, Y.; Gutwein, P.; Altevogt, P. L1-CAM in a membrane- bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol.Oncol. 2007, 2, 461-469.
14. Schafer, H.; Dieckmann, C.; Korniienko, O.; Moldenhauer, G.; Kiefel, H.; Salnikov, A.; Kruger, A.; Altevogt, P.; Sebens, S. Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma. Cancer Lett. 2012, 1, 66-82.
15. Eberle, K.E.; Sansing, H.A.; Szaniszlo, P.; Resto, V.A.; Berrier, A.L. Carcinoma matrix controls resistance to cisplatin through talin regulation of NF-kB. PLoS One 2011, 6, e21496.
16. Hazlehurst, L.A.; Enkemann, S.A.; Beam, C.A.; Argilagos, R.F.; Painter, J.; Shain, K.H.; Saporta, S.; Boulware, D.; Moscinski, L.; Alsina, M., et al. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model. Cancer Res. 2003, 22, 7900-7906.
17. Holmgren, L.; O'Reilly, M.S.; Folkman, J. Dormancy of micro metastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995, 2, 149-153.
18. Carmeliet, P.; Jain, R.K. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 7347, 298-307.
19. Ferrara, N.; Gerber, H.P.; Le Couter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 6, 669-676.
20. Hicklin, D.J.; Ellis, L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 2005, 5, 1011-1027.
21. Schwartz, J.D.; Rowinsky, E.K.; Youssoufian, H.; Pytowski, B.; Wu, Y. Vascular endothelial growth factor receptor-1 in human cancer: Concise review and rationale for development of IMC- 18F1 (Human antibody targeting vascular endothelial growth factor receptor-1). Cancer 2010, 4, S1027-S1032.
22. Dias, S.; Hattori, K.; Zhu, Z.; Heissig, B.; Choy, M.; Lane, W.; Wu, Y.; Chadburn, A.; Hyjek, E.; Gill, M., et al. Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration. J. Clin. Invest. 2000, 4, 511-521.
23. Harmey, J.H.; Bouchier-Hayes, D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: Implications for anti-angiogenic therapy. Bioessays 2002, 3, 280-283.
24. Zhang, L.; Hannay, J.A.; Liu, J.; Das, P.; Zhan, M.; Nguyen, T.; Hicklin, D.J.; Yu, D.; Pollock, R.E.; Lev, D. Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: Implications for tumor growth, metastasis, and chemoresistance. Cancer Res. 2006, 17, 8770-8778.
25. Yang, F.; Tang, X.; Riquelme, E.; Behrens, C.; Nilsson, M.B.; Giri, U.; Varella-Garcia, M.; Byers, L.A.; Lin, H.Y.; Wang, J., et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011, 16, 5512-5521.
26. Tran, J.; Master, Z.; Yu, J.L.; Rak, J.; Dumont, D.J.; Kerbel, R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl Acad Sci. USA 2002, 7, 4349-4354.
27. Fukuda, S.; Pelus, L.M. Survivin, a cancer target with an emerging role in normal adult tissues. Mol. Cancer Ther. 2006, 5, 1087-1098.
28. Nor, J.E.; Christensen, J.; Mooney, D.J.; Polverini, P.J. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am. J. Pathol. 1999, 2, 375-384.
29. Samuel, S.; Fan, F.; Dang, L.H.; Xia, L.; Gaur, P.; Ellis, L.M. Intracrine vascular endothelial growth factor signaling in survival and chemoresistance of human colorectal cancer cells. Oncogene 2011, 10, 1205-1212.
30. Dias, S.; Shmelkov, S.V.; Lam, G.; Rafii, S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 7, 2532-2540.
31. Fujio, Y.; Walsh, K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J. Biol. Chem. 1999, 23, 16349-16354.
32. Wang, L.; Chen, L.; Benincosa, J.; Fortney, J.; Gibson, L.F. VEGF-induced phosphorylation of Bcl-2 influences B lineage leukemic cell response to apoptotic stimuli. Leukemia 2005, 3, 344-353.
33. Pidgeon, G.P.; Barr, M.P.; Harmey, J.H.; Foley, D.A.; Bouchier-Hayes, D.J. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br. J. Cancer 2001, 2, 273-278.
34. Lee, Y.K.; Shanafelt, T.D.; Bone, N.D.; Strege, A.K.; Jelinek, D.F.; Kay, N.E. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: Implication for apoptosis resistance. Leukemia 2005, 4, 513-523.
35. Gerhardt, H.; Betsholtz, C. Endothelial-pericyte interactions in angiogenesis. Cell Tissue Res. 2003, 1, 15-23.
36. Franco, M.; Roswall, P.; Cortez, E.; Hanahan, D.; Pietras, K. Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression. Blood 2011, 10, 2906-2917.
37. Ferrari, G.; Pintucci, G.; Seghezzi, G.; Hyman, K.; Galloway, A.C.; Mignatti, P. VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc. Natl. Acad Sci. USA 2006, 46, 17260-17265.
38. Michaelis, M.; Klassert, D.; Barth, S.; Suhan, T.; Breitling, R.; Mayer, B.; Hinsch, N.; Doerr, H.W.; Cinatl, J.; Cinatl, J., Jr. Chemo resistance acquisition induces a global shift of expression of aniogenesis-associated genes and increased pro-angogenic activity in neuroblastoma cells. Mol. Cancer 2009, doi:10.1186/1476-4598-8-80.
39. Biroccio, A.; Candiloro, A.; Mottolese, M.; Sapora, O.; Albini, A.; Zupi, G.; del Bufalo, D. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J. 2000, 5, 652-660.
40. Anai, S.; Goodison, S.; Shiverick, K.; Hirao, Y.; Brown, B.D.; Rosser, C.J. Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts. Mol. Cancer Ther. 2007, 1, 101-111.
41. Tu, S.P.; Cui, J.T.; Liston, P.; Huajiang, X.; Xu, R.; Lin, M.C.; Zhu, Y.B.; Zou, B.; Ng, S.S.; Jiang, S.H., et al. Gene therapy for colon cancer by adeno-associated viral vector-mediated transfer of survivin Cys84Ala mutant. Gastroenterology 2005, 2, 361-375.
42. Fuks, Z.; Persaud, R.S.; Alfieri, A.; McLoughlin, M.; Ehleiter, D.; Schwartz, J.L.; Seddon, A.P.; Cordon-Cardo, C.; Haimovitz-Friedman, A. Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res. 1994, 10, 2582-2590.
43. Karsan, A.; Yee, E.; Poirier, G.G.; Zhou, P.; Craig, R.; Harlan, J.M. Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am. J. Pathol. 1997, 6, 1775-1784.
44. O'Connor, D.S.; Schechner, J.S.; Adida, C.; Mesri, M.; Rothermel, A.L.; Li, F.; Nath, A.K.; Pober, J.S.; Altieri, D.C. Control of apoptosis during angiogenesis by survivin expression in endothelial cells. Am. J. Pathol. 2000, 2, 393-398.
45. Carmeliet, P.; Lampugnani, M.G.; Moons, L.; Breviario, F.; Compernolle, V.; Bono, F.; Balconi, G.; Spagnuolo, R.; Oosthuyse, B.; Dewerchin, M., et al. Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 1999, 2, 147-157.
46. Chavakis, E.; Dimmeler, S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol 2002, 6, 887-893.
47. Brown, C.K.; Khodarev, N.N.; Yu, J.; Moo-Young, T.; Labay, E.; Darga, T.E.; Posner, M.C.; Weichselbaum, R.R.; Mauceri, H.J. Glioblastoma cells block radiation-induced programmed cell death of endothelial cells. FEBS Lett. 2004, 1-3, 167-170.
48. Fonsato, V.; Buttiglieri, S.; Deregibus, M.C.; Puntorieri, V.; Bussolati, B.; Camussi, G. Expression of Pax2 in human renal tumor-derived endothelial cells sustains apoptosis resistance and angiogenesis. Am. J. Pathol. 2006, 2, 706-713.
49. Virrey, J.J.; Guan, S.; Li, W.; Schonthal, A.H.; Chen, T.C.; Hofman, F.M. Increased surviving expression confers chemoresistance to tumor-associated endothelial cells. Am. J. Pathol. 2008, 2, 575-585.
50. Meng, F.; Henson, R.; Patel, T. Chemotherapeutic stress selectively activates NF-kappa B- dependent AKT and VEGF expression in liver cancer-derived endothelial cells. Am. J. Physiol. Cell Physiol. 2007, 2, C749-C760.
51. Kim, K.J.; Li, B.; Winer, J.; Armanini, M.; Gillett, N.; Phillips, H.S.; Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993, 6423, 841-844.
52. Lee, C.G.; Heijn, M.; di Tomaso, E.; Griffon-Etienne, G.; Ancukiewicz, M.; Koike, C.; Park, K.R.; Ferrara, N.; Jain, R.K.; Suit, H.D.; Boucher, Y. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under nor moxic or hypoxic conditions. Cancer Res. 2000, 19, 5565-5570.
53. Tong, R.T.; Boucher, Y.; Kozin, S.V.; Winkler, F.; Hicklin, D.J.; Jain, R.K. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004, 11, 3731-3736.
54. Oreilly, M.S.; Holmgren, L.; Chen, C.; Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 1996, 6, 689-692.
55. Carmeliet, P.; Jain, R.K. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat. Rev. Drug Discov. 2011, 6, 417-427.
56. Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 2, 145-147.
57. Xu, T.; Chen, J.; Lu, Y.; Wolff, J.E. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: A systematic review and survival-gain analysis. BMC Cancer 2010, doi:10.1186/1471-2407-10-252.
58. Mayer, R.J. Two steps forward in the treatment of colorectal cancer. N. Engl. J. Med. 2004, 23, 2406-2408.
59. Jain, R.K. Normalization of tumor vasculature: An emerging concept in antian giogenic therapy. Science 2005, 5706, 58-62.
60. De Bock, K.; Mazzone, M.; Carmeliet, P. Antiangiogenic therapy, hypoxia, and metastasis: Risky liaisons, or not? Nat. Rev. Clin. Oncol. 2011, 7, 393-404.
61. Brahimi-Horn, M.C.; Bellot, G.; Pouyssegur, J. Hypoxia and energetic tumour metabolism. Curr.Opin.Genet. Dev. 2011, 1, 67-72.
62. Bottaro, D.P.; Liotta, L.A. Cancer: Out of air is not out of action. Nature 2003, 6940, 593-595.
63. Semenza, G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 10, 721-732.
64. Liu, Y.; Cox, S.R.; Morita, T.; Kourembanas, S. Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5' enhancer. Circ. Res. 1995, 3, 638-643.
65. Eltzschig, H.K.; Carmeliet, P. Hypoxia and inflammation. N. Engl. J. Med. 2011, 7, 656-665.
66. Blagosklonny, M.V. Antiangiogenic therapy and tumor progression. Cancer Cell 2004, 1, 13-17.
67. Ebos, J.M.; Lee, C.R.; Cruz-Munoz, W.; Bjarnason, G.A.; Christensen, J.G.; Kerbel, R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 3, 232-239.
68. Paez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Vinals, F.; Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 3, 220-231.
69. Miles, D.W.; Chan, A.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.H.; Provencher, L.; Puglisi, F., et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 20, 3239-3247.
70. Padera, T.P.; Kuo, A.H.; Hoshida, T.; Liao, S.; Lobo, J.; Kozak, K.R.; Fukumura, D.; Jain, R.K. Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol. Cancer Ther. 2008, 8, 2272-2279.
71. Thomas, X.; Anglaret, B.; Magaud, J.P.; Epstein, J.; Archimbaud, E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk. Lymphoma 1998, 32, 107-119.
72. Shain, K.H.; Landowski, T.H.; Dalton, W.S. The tumor microenvironment as a determinant of cancer cell survival: A possible mechanism for de novo drug resistance. Curr. Opin. Oncol. 2000, 6, 557-563.
73. Xing, F.; Saidou, J.; Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 2010, 15, 166-179.
74. Sirica, A.E. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 2012, 1, 44-54.
75. Fingas, C.D.; Bronk, S.F.; Werneburg, N.W.; Mott, J.L.; Guicciardi, M.E.; Cazanave, S.C.; Mertens, J.C.; Sirica, A.E.; Gores, G.J. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology 2011, 6, 2076-2088.
76. Ruan, K.; Bao, S.; Ouyang, G. The multifaceted role of periostin in tumorigenesis. Cell Mol. Life Sci. 2009, 14, 2219-2230.
77. Park, J.E.; Lenter, M.C.; Zimmermann, R.N.; Garin-Chesa, P.; Old, L.J.; Rettig, W.J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem. 1999, 51, 36505-36512.
78. Heldin, C.H.; Rubin, K.; Pietras, K.; Ostman, A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat. Rev. Cancer 2004, 10, 806-813.
79. Serebriiskii, I.; Castello-Cros, R.; Lamb, A.; Golemis, E.A.; Cukierman, E. Fibroblast-derived 3D matrix differentially regulates the growth and drug-responsiveness of human cancer cells. Matrix. Biol. 2008, 6, 573-585.
80. Muerkoster, S.S.; Werbing, V.; Koch, D.; Sipos, B.; Ammerpohl, O.; Kalthoff, H.; Tsao, M.S.; Folsch, U.R.; Schafer, H. Role of myofibroblasts in innate chemoresistance of pancreatic carcinoma--epigenetic downregulation of caspases. Int. J. Cancer 2008, 8, 1751-1760.
81. Reardon, D.A.; Akabani, G.; Coleman, R.E.; Friedman, A.H.; Friedman, H.S.; Herndon, J.E.; McLendon, R.E.; Pegram, C.N.; Provenzale, J.M.; Quinn, J.A., et al. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. 2006, 1, 115-122.
82. Loeffler, M.; Kruger, J.A.; Niethammer, A.G.; Reisfeld, R.A. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 2006, 7, 1955-1962.
83. Ringe, J.; Strassburg, S.; Neumann, K.; Endres, M.; Notter, M.; Burmester, G.R.; Kaps, C.; Sittinger, M. Towards in situ tissue repair: Human mesenchymal stem cells express chemokine receptors CXCR1, CXCR2 and CCR2, and migrate upon stimulation with CXCL8 but not CCL2. J. Cell Biochem. 2007, 1, 135-146.
84. Pasquet, M.; Golzio, M.; Mery, E.; Rafii, A.; Benabbou, N.; Mirshahi, P.; Hennebelle, I.; Bourin, P.; Allal, B.; Teissie, J., et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int. J. Cancer 2010, 9, 2090-2101.
85. Rhodes, L.V.; Muir, S.E.; Elliott, S.; Guillot, L.M.; Antoon, J.W.; Penfornis, P.; Tilghman, S.L.; Salvo, V.A.; Fonseca, J.P.; Lacey, M.R., et al. Adult human mesenchymal stem cells enhance breast tumorigenesis and promote hormone independence. Breast Cancer Res. Treat. 2010, 2, 293-300.
86. Karnoub, A.E.; Dash, A.B.; Vo, A.P.; Sullivan, A.; Brooks, M.W.; Bell, G.W.; Richardson, A.L.; Polyak, K.; Tubo, R.; Weinberg, R.A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 7162, 557-563.
87. Xu, Y.; Tabe, Y.; Jin, L.; Watt, J.; McQueen, T.; Ohsaka, A.; Andreeff, M.; Konopleva, M. TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells. Br. J. Haematol. 2008, 2, 192-201.
88. Hao, M.; Zhang, L.; An, G.; Meng, H.; Han, Y.; Xie, Z.; Xu, Y.; Li, C.; Yu, Z.; Chang, H.; Qiu, L. Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leuk. Lymphoma 2011, 9, 1787-1794.
89. Jin, L.; Tabe, Y.; Konoplev, S.; Xu, Y.; Leysath, C.E.; Lu, H.; Kimura, S.; Ohsaka, A.; Rios, M.B.; Calvert, L., et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol. Cancer Ther. 2008, 1, 48-58.
90. Benito, J.; Shi, Y.; Szymanska, B.; Carol, H.; Boehm, I.; Lu, H.; Konoplev, S.; Fang, W.; Zweidler-Ckay, P.A.; Campana, D., et al. Pronounced hypoxia in models of murine and human leukemia: High efficacy of hypoxia-activated prodrug PR-104. PLoS One 2011, 8, e23108.
91. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 5, 646-674.
92. Igney, F.H.; Krammer, P.H. Immune escape of tumors: Apoptosis resistance and tumor counterattack. J. Leukoc. Biol. 2002, 6, 907-920.
93. Shojaei, F.; Wu, X.; Malik, A.K.; Zhong, C.; Baldwin, M.E.; Schanz, S.; Fuh, G.; Gerber, H.P.; Ferrara, N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 8, 911-920.
94. Fischer, C.; Jonckx, B.; Mazzone, M.; Zacchigna, S.; Loges, S.; Pattarini, L.; Chorianopoulos, E.; Liesenborghs, L.; Koch, M.; de Mol, M., et al. Anti-PlGF inhibits growth of VEGF(R)- inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 3, 463-475.
95. Biswas, S.K.; Sica, A.; Lewis, C.E. Plasticity of macrophage function during tumor progression: Regulation by distinct molecular mechanisms. J. Immunol. 2008, 4, 2011-2017.
96. Denardo, D.G.; Brennan, D.J.; Rexhepaj, E.; Ruffell, B.; Shiao, S.L.; Madden, S.F.; Gallagher, W.M.; Wadhwani, N.; Keil, S.D.; Junaid, S.A., et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 2011, doi:10.1158/2159-8274.
97. Shree, T.; Olson, O.C.; Elie, B.T.; Kester, J.C.; Garfall, A.L.; Simpson, K.; Bell-McGuinn, K.M.; Zabor, E.C.; Brogi, E.; Joyce, J.A. Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. Genes Dev. 2011, 23, 2465-2479.
98. Angst, E.; Reber, H.A.; Hines, O.J.; Eibl, G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 2008, 1, 57-65.
99. Halama, N.; Michel, S.; Kloor, M.; Zoernig, I.; Pommerencke, T.; von Knebel Doeberitz, M.; Schirmacher, P.; Weitz, J.; Grabe, N.; Jager, D. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 2009, 9, 1.
100. Halama, N.; Michel, S.; Kloor, M.; Zoernig, I.; Benner, A.; Spille, A.; Pommerencke, T.; von Knebel, D.M.; Folprecht, G.; Luber, B., et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Res. 2011, 17, 5670-5677.
101. Denkert, C.; Loibl, S.; Noske, A.; Roller, M.; Muller, B.M.; Komor, M.; Budczies, J.; Darb-Esfahani, S.; Kronenwett, R.; Hanusch, C., et al. Tumor-associated lymphocytes as an independent redictor of response to neoadjuvant chemotherapy in breast cancer. J. Clin. Oncol. 2010, 1, 105-113.
102. Van der Most, R.G.; Currie, A.J.; Cleaver, A.L.; Salmons, J.; Nowak, A.K.; Mahendran, S.; Larma, I.; Prosser, A.; Robinson, B.W.; Smyth, M.J., et al. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One 2009, 9, e6982.
103. Ramakrishnan, R.; Assudani, D.; Nagaraj, S.; Hunter, T.; Cho, H.I.; Antonia, S.; Altiok, S.; Celis, E.; Gabrilovich, D.I. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 2010, 4, 1111-1124.
104. Mattarollo, S.R.; Loi, S.; Duret, H.; Ma, Y.; Zitvogel, L.; Smyth, M.J. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors. Cancer Res. 2011, 14, 4809-4820.
105. Ma, Y.; Aymeric, L.; Locher, C.; Mattarollo, S.R.; Delahaye, N.F.; Pereira, P.; Boucontet, L.; Apetoh, L.; Ghiringhelli, F.; Casares, N., et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J. Exp. Med. 2011, 3, 491-503.
106. Liu, H.; Zhang, T.; Ye, J.; Li, H.; Huang, J.; Li, X.; Wu, B.; Huang, X.; Hou, J. Tumorinfiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol. Immunother. 2012, doi:10.1007/s00262-012-1231-7.
107. Gobert, M.; Treilleux, I.; Bendriss-Vermare, N.; Bachelot, T.; Goddard-Leon, S.; Arfi, V.; Biota, C.; Doffin, A.C.; Durand, I.; Olive, D., et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res. 2009, 5, 2000-2009.
108. Bates, G.J.; Fox, S.B.; Han, C.; Leek, R.D.; Garcia, J.F.; Harris, A.L.; Banham, A.H. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 2006, 34, 5373-5380.
109. Tosolini, M.; Kirilovsky, A.; Mlecnik, B.; Fredriksen, T.; Mauger, S.; Bindea, G.; Berger, A.; Bruneval, P.; Fridman, W.H.; Pages, F., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res.2011, 4, 1263-1271.
110. Denardo, D.G.; Barreto, J.B.; Andreu, P.; Vasquez, L.; Tawfik, D.; Kolhatkar, N.; Coussens, L.M. CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. Cancer Cell 2009, 2, 91-102.
111. Stassi, G.; Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; di Liberto, D.; Patti, M.; Florena, A.; di Gaudio, F.; di Gesu, G.; de Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 20, 6784-6790.
112. Stassi, G.; Todaro, M.; Zerilli, M.; Ricci-Vitiani, L.; di Liberto, D.; Patti, M.; Florena, A.; di Gaudio, F.; di Gesu, G.; de Maria, R. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res. 2003, 20, 6784-6790.
113. Zou, W.; Restifo, N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat. Rev. Immunol. 2010, 4, 248-256.
114. Ding, Z.C.; Zhou, G. Cytotoxic chemotherapy and CD4+ effector T cells: An emerging alliance for durable antitumor effects. Clin. Dev. Immunol. 2012, doi:10.1155/2012/890178.
115. Pittoni, P.; Piconese, S.; Tripodo, C.; Colombo, M.P. Tumor-intrinsic and-extrinsic roles of c-Kit: Mast cells as the primary off-target of tyrosine kinase inhibitors. Oncogene 2011, 7, 757-769.
116. Johansson, A.; Rudolfsson, S.; Hammarsten, P.; Halin, S.; Pietras, K.; Jones, J.; Stattin, P.; Egevad, L.; Granfors, T.; Wikstrom, P., et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am. J. Pathol. 2010, 2, 1031-1041.
117. Pittoni, P.; Colombo, M.P. The dark side of mast cell-targeted therapy in prostate cancer. Cancer Res. 2012, 4, 831-835.
118. Iyengar, P.; Combs, T.P.; Shah, S.J.; Gouon-Evans, V.; Pollard, J.W.; Albanese, C.; Flanagan, L.; Tenniswood, M.P.; Guha, C.; Lisanti, M.P., et al. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Oncogene 2003, 41, 6408-6423.
119. Behan, J.W.; Yun, J.P.; Proektor, M.P.; Ehsanipour, E.A.; Arutyunyan, A.; Moses, A.S.; Avramis, V.I.; Louie, S.G.; Butturini, A.; Heisterkamp, N., et al. Adipocytes impair leukemia treatment in mice. Cancer Res. 2009, 19, 7867-7874.
120. Bochet, L.; Meulle, A.; Imbert, S.; Salles, B.; Valet, P.; Muller, C. Cancer-associated adipocytes promotes breast tumor radioresistance. Biochem. Biophys. Res. Commun. 2011, 1, 102-106.
121. Ma, J.; Dong, C.; Ji, C. MicroRNA and drug resistance. Cancer Gene Ther. 2010, 8, 523-531.
122. Sorrentino, A.; Liu, C.G.; Addario, A.; Peschle, C.; Scambia, G.; Ferlini, C. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol. Oncol 2008, 3, 478-486.
123. Wang, H.; Tan, G.; Dong, L.; Cheng, L.; Li, K.; Wang, Z.; Luo, H. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 2012, 4, e34210.
124. Zhao, R.; Wu, J.; Jia, W.; Gong, C.; Yu, F.; Ren, Z.; Chen, K.; He, J.; Su, F. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 2011, 12, 675-680.
125. Rao, E.; Jiang, C.; Ji, M.; Huang, X.; Iqbal, J.; Lenz, G.; Wright, G.; Staudt, L.M.; Zhao, Y.; McKeithan, T.W., et al. The miRNA-17 approximately 92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activation. Leukemia 2012, 5, 1064-1072.
126. Hamano, R.; Miyata, H.; Yamasaki, M.; Kurokawa, Y.; Hara, J.; Moon, J.H.; Nakajima, K.; Takiguchi, S.; Fujiwara, Y.; Mori, M., et al. Over expression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway. Clin. Cancer Res. 2011, 9, 3029-3038.
127. Kong, W.; He, L.; Coppola, M.; Guo, J.; Esposito, N.N.; Coppola, D.; Cheng, J.Q. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J. Biol. Chem. 2010, 23, 17869-17879.
128. Bourguignon, L.Y.; Earle, C.; Wong, G.; Spevak, C.C.; Krueger, K. Stem cell marker (Nanog) and Stat-3 signaling promote MicroRNA-21 expression and chemoresistance in hyaluronan/CD44-activated head and neck squamous cell carcinoma cells. Oncogene 2012, 2, 149-160.
129. Loscalzo, J. The cellular response to hypoxia: Tuning the system with micro RNAs. J. Clin. Invest. 2010, 11, 3815-3817.
130. Hebert, C.; Norris, K.; Scheper, M.A.; Nikitakis, N.; Sauk, J.J. High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol. Cancer 2007, 6, doi:10.1186/1476-4598-6-5.
131. Hanahan, D.; Coussens, L.M. Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 3, 309-322.
132. Margolin, D.A.; Silinsky, J.; Grimes, C.; Spencer, N.; Aycock, M.; Green, H.; Cordova, J.; Davis, N.K.; Driscoll, T.; Li, L. Lymph node stromal cells enhance drug-resistant colon cancer cell tumor formation through SDF-1alpha/CXCR4 paracrine signaling. Neoplasia. 2011, 9, 874-886.